Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine/etidronic acid

Drug Profile

Cytarabine/etidronic acid

Alternative Names: Etidronate/cytosine arabinoside; Etidronic acid/cytarabine; MBC 11; MBC-11 -29

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MBC Pharma
  • Developer MBC Pharma; Osteros Biomedica
  • Class Antihypercalcaemics; Antineoplastics; Arabinonucleosides; Bisphosphonates; Calcium regulators; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Bone metastases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bone metastases in Russia (IV)
  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Bone metastases presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top